- cafead Jun 06, 2023 at 04:22: PM
via The PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical Oncology's recent annual meeting, two trial failures for class leaders were on display.
article source
article source